

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Date: February 19, 2002

By: Kay L. Gaviglio

Kay L. Gaviglio

**PATENT**  
**Docket No. GC561-3C1**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Huaming Wang et al	)	Group Art Unit: Unassigned
	)	
Serial No.: Unassigned	)	Examiner: Unassigned
	)	
Filed: Herewith	)	
	)	
For: PHENOL OXIDIZING ENZYMES	)	

j1002 U.S. PTO  
10/080210  
02/19/02

**Information Disclosure Statement**

Box DD  
Commissioner for Patents  
Washington, DC 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☒ accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.
- (d) ☐ is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by

either the fee (\$180.00) set forth in 37 CFR §1.17(p) **or** a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.

(e) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(l)(1) **and** a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.**

**[If either of boxes (d) or (e) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.]** The undersigned certifies that:

☐ Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for PCT/  
\_\_\_\_\_, filed \_\_\_\_\_ with attached patents and publications.

☒ each ☐ none ☐ only those listed below:

Those patent(s) or publication(s) which are marked with an asterisk (\*) on the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Office in a prior application, Serial No. 09/338,723 filed June 23, 1999 and 09/468,578 filed December 21, 1999, and relied upon in this application for an earlier filing date under 35 USC 120.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s)

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,



H. Thomas Anderton  
Registration No. 40,895

Date: February 19, 2001

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650 846-7544  
Fax: 650 845-6504

INFORMATION DISCLOSURE CITATION	
Attorney Docket No.: GC561-3C1	Serial No.: Not Assigned
Applicant: Wang et al.	
Filing Date: Herewith	Group:
Page <u>1</u> of <u>1</u>	Date of this Submission: February 19, 2002

02 U.S. PTO  
 02/080210  
 02/19/02

1002 U.S. PTO  
10/080210  
02/19/02

Examiner's	Document				Sub-	Filing
Initial	Number	Date	Name	Class	Class	Date
	*6,072,015	06-2000	Bolle et al			
	*6,168,936	01-2001	Wang et al			

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	WO 98/27198	25/06/1998				
	WO 98/27197	25/06/1998				
	*WO 99/49020	30 Sept 1999	PCT			
	WO 99/49010	30 Sept 1999				
	*WO 00/05349	3 Feb 2000	PCT			
	*EP 0 852 260 A1	8 July 1998	European Patent Office			

OTHER DOCUMENTS	
Examiner's Initials	Author, Title, Date, Pertinent Pages, etc.
	*Koikeda, S. et al., "Molecular cloning of the gene for bilirubin oxidase from <i>Myrothecium verrucaria</i> and its expression in yeast," <i>Journal of Biological Chemistry</i> , V. 268(25) pp. 18801-18809 1993
	*Ishigami et al., "Purification and properties of polyphenol oxidase....." J. Gen. Appl. Microbiol. 32, 293-301 1986
	*Munzo et al., "Laccase isoenzymes of <i>Pleurotus eryngii</i> ...." Appl. Environm. Microbiol. 63 (6), 2166-2174 6/1997
	*Youn et al., "Single electron transfer by extracellular laccase from white-rot fungus...." Microbiology 141, 393-398 1995
	*Giardina et al. "Ligninolytic enzymes from <i>Pleurotus ostreatus</i> " Italian J. Biochem. 37(5), 345A-346A 9/1988
	* Patent Abstract of Japan, V. 017 (638) (c-1133), 26 November 1993 & JP 05 199881 A (Amano Pharmaceut Co. Ltd)
Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

PTO-1449